Tag: $Pfizer Inc

Pfizer (PFE), on Tuesday forecast 2026 profit below Wall Street estimates as it expects a steep drop in sales of its COVID products and a revenue hit from the loss of exclusivity on some drugs.

Shares of Metsera, fell nearly 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer, to end a fierce bidding war between the pharma giant and Danish rival Novo Nordisk.

Pfizer (PFE.N), on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations.

 Pfizer (PFE.N) and President Donald Trump on Tuesday said they had cut a deal in which the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program to what it charges in other developed countries in exchange for tariff relief.

 Pfizer (PFE.N), said on Monday it would acquire weight-loss drug developer Metsera (MTSR.O), in a deal valued at up to $7.3 billion, including future payments, to secure its position in the lucrative obesity treatment market.

Pfizer(PFE) raised its full-year earnings guidance as the drugmaker reported quarterly results way ahead of expectations early Tuesday, sending shares of the drugmaker up in premarket trading.

Pfizer stock fell after suffering a setback developing a new weight-loss drug.

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company’s Covid vaccine and antiviral pill Paxlovid helped boost sales.

Pfizer Inc.’s stock rose 2.7% early Tuesday, after the company blew past earnings estimates for the second quarter, offered an update on a cost-cutting plan and raised its revenue and profit guidance for the year.

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit.

Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products.

Pfizer Inc.’s stock tumbled 4% premarket Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects.

The European Commission has contracted Pfizer and several European companies to reserve capacity to make up to 325 million vaccines per year in case of a future global health emergency, it said on Friday.

Pfizer Inc said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice daily treatment danuglipron, as it races to rival the success of other weight loss treatments.